NCT05166304View on ClinicalTrials.gov

Rebamipide in Patients With Active Rheumatoid Arthritis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Rebamipide

patients will receive the standard therapy plus 100 mg Rebamipide three times daily

DRUG

Placebo

patients will receive the standard therapy (methotrexate) plus placebo tablets

Trial Locations (1)

Unknown

RECRUITING

Minia University, Minya

All Listed Sponsors
collaborator

Minia University, faculty of medicine

UNKNOWN

collaborator

Sohag University

OTHER

lead

October 6 University

OTHER